PCIB PCI Biotech Holding ASA

Minutes from Annual General Meeting 2023

Minutes from Annual General Meeting 2023

Oslo, 25 May 2023. The Annual General Meeting in PCI Biotech Holding ASA took place today, 25 May 2023.

All the matters on the agenda were approved and the minutes of the Annual General Meeting are attached to this release and are available on

Contact information:        

PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo        

Ronny Skuggedal, CEO / CFO, , Mobile:

This information is subject to a duty of disclosure pursuant to Section 5-12 of the Norwegian Securities Trading Act.

Attachment



EN
25/05/2023

Underlying

PCIBPCI Biotech Holding ASA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PCI Biotech Holding ASA

 PRESS RELEASE
Free
PCIB PCI Biotech Hol...

PCI Biotech: Employee share option scheme

PCI Biotech: Employee share option scheme Oslo, 2 September 2024 - PCI Biotech (OSE: PCIB), today announce that the Board of Directors has granted share options to key employees.         In accordance with the authorisation granted by the Annual General Meeting 24 May 2024 and the remuneration policy adopted by the Annual General Meeting 28 May 2021, the Board of Directors of PCI Biotech Holding ASA (“PCI Biotech”) has awarded a total of 885,000 share options to key employees. Each share option gives the right to subscribe for or acquire one share per option (after PCI Biotech’s choice), a...

September 2, 2024 1 EN
 PRESS RELEASE
Free
PCIB PCI Biotech Hol...

PCI Biotech first half 2024 interim results

PCI Biotech first half 2024 interim results Oslo (Norway), 28 August 2024 – PCI Biotech (OSE: PCIB), today announces its interim first half 2024 results. Please find enclosed the interim report and presentation.Highlights review OperationsPCI Biotech’s 2024 development goals are to demonstrate scalability and manufacturing process benefits for the photochemical-based technology (PCL) in viral vector manufacturing. Results reported in Q1 2024 from field testing of the technology with a European partner confirmed the potential benefit of applying photochemical methods in...

August 28, 2024 1 EN
 PRESS RELEASE
Free
PCIB PCI Biotech Hol...

PCI Biotech: Invitation to first half interim 2024 results presentatio...

PCI Biotech: Invitation to first half interim 2024 results presentation Oslo, Norway, 23 August 2024 - PCI Biotech (OSE: PCIB) invites to a webcast presentation of the company's first half 2024 interim report on Wednesday 28 August 2024, 08:30am – 09:00am CEST (local time). The presentation will be held as a live webcast available through The presentation will be held in Norwegian. There will be a Q&A session at the end of the presentation and it will be possible to post written questions through the webcast console. The interim report and presentation will be made available on and o...

August 23, 2024 1 EN
 PRESS RELEASE
Free
PCIB PCI Biotech Hol...

Minutes of Annual General Meeting 2024

Minutes of Annual General Meeting 2024 Oslo, 24 May 2024. The Annual General Meeting in PCI Biotech Holding ASA took place today, 24 May 2024. All the matters on the agenda were approved and the minutes of the Annual General Meeting are attached to this release and are available on Contact information:     PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo         Ronny Skuggedal, CEO / CFO, , Mobile: This information is subject to a duty of disclosure pursuant to Section 5-12 of the Norwegian Securities Trading Act. Attachment ...

May 24, 2024 1 EN
 PRESS RELEASE
Free
PCIB PCI Biotech Hol...

Disclosure of voting rights for Chair of the Board

Disclosure of voting rights for Chair of the Board Oslo, 23 May 2024. PCI Biotech Holding ASA ("PCI Biotech" or the "Company") issue this notification on behalf of Hans Peter Bøhn, Chair of the Board of Directors. Hans Peter Bøhn is chair of PCI Biotech’s board of directors and shall open the annual general meeting of the Company on 24 May 2024. Mr. Bøhn holds 123,662 shares, representing 0.3 percent of the share capital of PCI Biotech. Mr. Bøhn has received powers of attorney to represent and vote for 4,288,185 additional shares. In total, Mr. Bøhn will represent and vote for 11.8 percent...

May 23, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch